Thelansis

Chronic Pancreatitis Market Outlook Thelansis’s “Chronic Pancreatitis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Pancreatitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? W...

Chronic Pancreatitis Market Outlook Thelansis’s “Chronic Pancreatitis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Pancreatitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Chronic Pancreatitis Overview Chronic pancreatitis is a progressive inflammatory condition that results in the irreversible destruction of both exocrine and endocrine pancreatic tissue, typically due to atrophy or its replacement with fibrous tissue. This disorder gives rise to significant functional consequences, including intense abdominal pain, diabetes mellitus, and malabsorption of nutrients. Chronic pancreatitis can be triggered by vario...

 Chronic pancreatitis is a progressive inflammatory condition that results in the irreversible destruction of both exocrine and endocrine pancreatic tissue, typically due to atrophy or its replacement with fibrous tissue. This disorder gives rise to significant functional consequences, including intense abdominal pain, diabetes mellitus, and malabsorption of nutrients. Chronic pancreatitis can be triggered by various factors, including alcohol abuse, blockage of the pancreatic ducts (caused by malignancies, stones, or trauma), genetic predisposition, chemotherapy, and autoimmune diseases such as systemic lupus erythematosus (SLE) or autoimmune pancreatitis. Laboratory tests used for diagnosing chronic pancreatitis encompass a complete blood count (CBC), basic metabolic panel (BMP), liver function tests (LFTs), lipase, amylase, lipid panel, and measurement of fecal elastase-1 levels. Lipase and amylase levels may exhibit elevation, although they tend to be normal due to significant ...

  Chronic pancreatitis is a multifactorial, fibroinflammatory syndrome characterised by recurrent episodes of pancreatic inflammation that result in extensive fibrotic tissue replacement, resulting in chronic pain, exocrine and endocrine pancreatic insufficiency, decreased quality of life, and a shorter life expectancy. Thelansis’s “Chronic Pancreatitis Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Pancreatitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Chronic Pancreatitis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around cur...

Chronic pancreatitis is a multifactorial, fibroinflammatory syndrome in which repetitive episodes of pancreatic inflammation lead to extensive fibrotic tissue replacement, resulting in chronic pain, exocrine and endocrine pancreatic insufficiency, reduced quality of life, and a shorter life expectancy. Etiology- The TIGAR-O classification system, identifies 6 major etiologies for Chronic pancreatitis :  toxic/metabolic (T), idiopathic (I), genetic (G), autoimmune (A), recurrent and severe acute pancreatitis (R), and obstruction (O).   Epidemiology- The prevalence between 2001 and 2013 of adult US Americans with health insurance (48·67 million) was 25·4–98·7 per 100000 people, depending on search criteria, with a small increase in the male to female ratio of 1·05 (75·2 men vs 71·8 women per 100000 people), peaking in patients aged 46–55 years.16 The incidence is estimated to be four to five new cases per 100000 per year, thus confirming data from a comprehensive population-base...